经FDA批准,使用莱纳卡巴维尔抑制HIV-1囊体:暴露前预防的范式转变
Kashaf Sanaullah1, Abdul Haseeb Hasan1, Muhammad Ali Abid1
1Medicine, King Edward Medical University, Lahore, PAK.
Cureus
|October 14, 2025
概括
莱纳卡帕维尔 (Lenacapavir) 是一种新的每年两次注射的HIV-1囊抑制剂,与每日口服选择相比,在暴露前预防 (PrEP) 中表现出更高的疗效. 这一进步为预防艾滋病毒提供了新的希望,解决了坚持的障碍.
科学领域:
- 传染性疾病 传染性疾病
- 病毒学 病毒学
- 药理学 药理学是指药理学的学科.
背景情况:
- 人类免疫缺陷病毒1型 (HIV-1) 感染影响全球超过4000万人.
- 坚持每日口服抗逆转录病毒疗法和暴露前预防 (PrEP) 是一个重大挑战,限制了它们的有效性.
- 莱纳卡帕维尔提供了一种新的,长效的预防策略来预防HIV-1.
研究的目的:
- 评估lenacapavir在HIV-1暴露前预防 (PrEP) 中的疗效和安全性.
- 为了比较每年两次皮下注射莱纳卡帕维尔与每日口服PrEP疗程的有效性.
- 评估lenacapavir在不同人群中克服粘附障碍的潜力.
主要方法:
- 进行了两项3期随机对照试验.
- 参与者接受了lenacapavir或标准口服PrEP疗法.
- 用HIV-1感染率来衡量有效性,并监测安全性,包括注射部位反应.
主要成果:
- 与口服PrEP相比,莱纳卡巴维尔在预防HIV-1感染方面表现出更高的疗效.
- 在各种人群中观察到几乎完全的预防,包括cisgender女性,男性和性别多元的个人.
- 可接受的安全性概况,常见的注射部位反应;耐药性风险需要剂量前的HIV检测.
结论:
- 每年两次服用莱纳卡帕维尔是一种高效的HIV-1 PrEP选择,解决了坚持的挑战.
- 实施需要解决方案性培训,药物相互作用和现有的PrEP吸收差异.
- 莱纳卡巴维尔代表了预防艾滋病毒的重大进步,在等待监管批准和公平获取战略之前,它有可能对全球产生影响.
相关概念视频
Retrovirus Life Cycles
49.3K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.3K
Retroviruses
14.6K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
14.6K


